OP-ED | Julie Spony on "Supporting patient-centred innovation: the value of patient experience data"

One key priority for EPF is to ensure that patients have access to the medicines they need. For many patients with chronic diseases, medicines are an essential part of their treatment. Medicines offer the promise of a significant improvement in health or quality of life, or even a cure. Read the latest op-ed on the value of patient experience data (PED).

Access to medicines is not only a question of availability, affordability and accessibility, but also of adequacy and appropriateness. Medicines must be safe, of high quality and effective, and they must also address patients’ needs, as defined by patients themselves.

The inclusion of patient experience data (PED) at all stages of medicine development and regulatory decision-making ensures that new medicines address the outcomes and preferences that matter to patients.

Read more here.